Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
0.2921
-0.0150 (-4.87%)
Aug 4, 2025, 2:02 PM - Market open

Verve Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2020
Net Income
-11.87-14.1-14.58-12.09-12.75-4.6
Upgrade
Stock-Based Compensation
2.683.443.773.36.071.48
Upgrade
Other Operating Activities
----1.520.57
Upgrade
Change in Accounts Payable
-0.20.20.981.220.39-0.8
Upgrade
Change in Other Net Operating Assets
0.030.080.030.03-0.25-0
Upgrade
Operating Cash Flow
-9.37-10.38-9.8-7.54-5.01-3.35
Upgrade
Long-Term Debt Issued
-----0.07
Upgrade
Net Debt Issued (Repaid)
-----0.07
Upgrade
Issuance of Common Stock
5.096.628.163.714.83.98
Upgrade
Financing Cash Flow
5.096.628.163.714.84.04
Upgrade
Net Cash Flow
-4.28-3.77-1.64-3.859.780.69
Upgrade
Levered Free Cash Flow
-4.87-5.09-4.33-3.01-0.21-2.08
Upgrade
Unlevered Free Cash Flow
-4.87-5.09-4.33-3.01-0.21-2.08
Upgrade
Change in Net Working Capital
0.59-0.28-1.01-1.25-0.141.26
Upgrade
Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q